<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779879</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-7831-5006</org_study_id>
    <secondary_id>GSK Study 216912</secondary_id>
    <nct_id>NCT04779879</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19</brief_title>
  <acronym>COMET-PEAK</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vir Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will&#xD;
      receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2&#xD;
      (Gen2) and will be assessed for safety, tolerability, and pharmacokinetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part A is double-blinded. Parts B and C are open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs) in Part A participants</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs) in Part A participants</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events of special interest (AESIs) in Part A participants</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) in Part A participants readings</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of disease progression events (not classified as AEs) in Part A participants</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part B study participants</measure>
    <time_frame>Day 1 through Day 8</time_frame>
    <description>Measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in nasopharyngeal swab samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part C study participants</measure>
    <time_frame>Day 1 through Day 8</time_frame>
    <description>Measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in nasopharyngeal swab samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clast</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCD0-28</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCexp</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of SAEs in Part A participants</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of AESIs in Part A participants</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically significant abnormalities on 12-lead ECG readings in Part A participants</measure>
    <time_frame>Through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of disease progression events (not classified as AEs) in Part A participants</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of non-serious AEs in Part A participants</measure>
    <time_frame>Through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events (AEs) in Parts B and C participants</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events (SAEs) in Parts B and C participants</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events of special interest (AESIs) in Parts B and C participants</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) in Parts B and C participants</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of disease progression events (not classified as AEs) in Parts B and C participants</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of non-serious AEs in Parts B and C participants</measure>
    <time_frame>Through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of SAEs in Parts B and C participants</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of AESIs in Parts B and C participants</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically significant abnormalities on 12-lead ECG readings in Parts B and C participants</measure>
    <time_frame>Through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of disease progression events (not classified as AEs) in Parts B and C participants</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral load at all visits in Part A participants</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Measured by qRT-PCR from saliva and nasal mid-turbinate swabs samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral load at all visits in Parts B and C participants</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Measured by qRT-PCR from nasopharyngeal (NP) swab samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with undetectable viral load at all visits in Parts B and C participants</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Measured by qRT-PCR from nasopharyngeal (NP) swab samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean area under the curve of SARS-CoV-2 viral load in Parts B and C participants</measure>
    <time_frame>Day 1 through Day 5 and Day 1 through Day 11</time_frame>
    <description>Measured by qRT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals with a persistently high viral load in Parts B and C participants</measure>
    <time_frame>Day 8</time_frame>
    <description>Assessed via qRT-PCR in NP swab samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of SARS-CoV-2 viral resistance mutants</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (if applicable) of serum anti-drug antibodies (ADA) to VIR-7831</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers (if applicable) of serum anti-drug antibodies (ADA) to VIR-7831</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (if applicable) of anti-nucleocapsid (anti-N), anti-spike (anti-S) and anti-receptor binding domain (anti-RBD) SARS-CoV-2 antibodies</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers (if applicable) of anti-nucleocapsid (anti-N), anti-spike (anti-S) and anti-receptor binding domain (anti-RBD) SARS-CoV-2 antibodies</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence (if applicable) of anti-N SARS-CoV-2 antibodies</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers (if applicable) of anti-N SARS-CoV-2 antibodies</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of SARS-CoV-2 viral resistance mutants</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Sotrovimab (Gen1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part A (double-blinded) participants will be randomized to receive 500 mg of an IV infusion of Sotrovimab Gen 1 material or 500 mg of an IV infusion of VIR-7831 Gen 2 material</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotrovimab (Gen2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part B (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or by IM injection&#xD;
Part C (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or 250 mg by IM injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sotrovimab (Gen1)</intervention_name>
    <description>Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material</description>
    <arm_group_label>Sotrovimab (Gen1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sotrovimab (Gen2)</intervention_name>
    <description>Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection</description>
    <arm_group_label>Sotrovimab (Gen1)</arm_group_label>
    <arm_group_label>Sotrovimab (Gen2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Part A, participants must be aged 18 years or older at the time of obtaining&#xD;
             informed consent&#xD;
&#xD;
          -  For Parts B and C, participants must be aged between 18 years and 69 years old at the&#xD;
             time of obtaining informed consent&#xD;
&#xD;
          -  Participants who have a positive SARS-CoV-2 test result ≤7 days prior to enrollment&#xD;
             and oxygen saturation ≥94% on room air and have COVID-19 symptoms and ≤7 days from&#xD;
             onset of symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently hospitalized or judged by the investigator as likely to require&#xD;
             hospitalization in the next 24 hours&#xD;
&#xD;
          -  Symptoms consistent with severe COVID-19&#xD;
&#xD;
          -  Participants who, in the judgement of the investigator are likely to die in the next 7&#xD;
             days.&#xD;
&#xD;
          -  Severely immunocompromised participants&#xD;
&#xD;
          -  For Parts A and B, prior receipt of a SARS-CoV-2 vaccine at any time prior to&#xD;
             enrollment (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be&#xD;
             allowed for 90 days after dosing)&#xD;
&#xD;
          -  For Parts B and C, conditions that would prohibit receipt of IM injections in the&#xD;
             investigator's opinion&#xD;
&#xD;
          -  For Parts A, B and C, receipt of any vaccine within 48 hours prior to enrollment&#xD;
             (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be allowed for&#xD;
             90 days after dosing)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Centelles</city>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>La Roca Del Vallès</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>coronavirus</keyword>
  <keyword>coronavirus disease 2019</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

